Exelixis (EXEL) is trading higher today as the stock digests a new Street note that nudged expectations upward. Barclays raised its price target on EXEL to $45 from $44 while maintaining an Equal Weight rating, a modest but supportive signal that helped lift sentiment in a tape where biotech often trades on incremental revisions to forward assumptions. (tipranks.com)

The timing is notable with the next earnings report expected in the early-to-mid May 2026 window based on market calendars, which often pulls incremental positioning into the name. With EXEL already near the mid-$40s, even small target changes can act as a catalyst for short-term flows as investors recalibrate near-term upside versus the consensus target range. (marketbeat.com)

Beyond the next quarterly print, investors continue to focus on Exelixis’ transition from a single-franchise story toward additional growth drivers, including zanzalintinib programs that management has positioned as major medium-term catalysts. Separately, Exelixis has emphasized capital return as part of its broader financial framework, keeping buybacks in the conversation as a technical support for the stock. (ir.exelixis.com)

At roughly $45 per share, EXEL is trading close to several published targets and within the band where incremental analyst revisions can meaningfully influence near-term momentum. The next leg likely depends on whether upcoming results and commentary strengthen confidence in 2026 revenue/profit delivery and the pace of pipeline-driven upside.